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Abstract
Loss of sensitivity to growth inhibition by transforming
growth factor (TGF)-1J is a phenomenon often observed
in human epithelial tumor cells and is linked to
malignant progression. We tested a panel of estrogen
receptor (ER)-positive and -negative breast cell lines for
their sensitivity to TGF-13 and a related member of the
TGF-fJ superfamily, activin. Both TGF-￿3-sensitive (MCF7,
Hs578T, and BT2O) and -resistant (two T47D variants,
ZR75-1, MDA-MB231, and MDA-MB468) cell lines were
found, with no strict correlation between ER content
and sensitivity to TGF4i. In contrast, all four ER-positive
cell lines were inhibited by activin A, whereas the ER-
negative lines were not. To examine whether resistance
to TGF-￿3 and activin resulted from the absence of the
corresponding receptors, mRNA expression of the types
I and II receptors was studied. TGF-13 receptor II was
not expressed in the two T47D variants and was low in
ZR75-1 cells. Upon stable transfection of the TGF-￿
receptor II in one of the T47D variants, sensitivity to
TGF-￿1 and TGF-fi2 was restored with respect to
inhibition of anchorage-dependent and -independent
proliferation, indicating that other signal transduction
components are functionally intact. Sensitivity to TGF-fJ
in the transfectants was dependent on the expression
level of the newly introduced receptor. Resistance to
activin in the ER-negative cell lines could be explained
in BT2O and Hs578T cells, but not in MDA-MB231 and
MDA-MB468, by low activin receptor expression. These
results show that resistance to TGF-j3 and activin is
often, but not always, due to reduced expression of the
signaling receptor in breast cancer cells. The activin
resistance of ER-negative breast tumor cells may be
involved in their increased malignancy compared with
ER-positive cells.
Introduction
Breast cancer is the most frequent malignancy offemales in
most Western countries, and estrogens play an important
role both in the development and proliferation of breast
tumors (1 ). Anti-estrogen therapy results in regression of
these tumors, but, due to loss of estrogen responsiveness,
this regression is often only temporary (2). The resulting
estrogen-independent tumor is not only resistant to anti-
estrogen therapy but also more aggressive.
Although estrogens are by far the most important hor-
mones that are known to stimulate mammary epithelial cell
proliferation, breast tumors express receptors for a large
variety of other hormones and polypeptide growth factors,
which may also influence their proliferation (3, 4). Hor-
monal regulation of these factors or their receptors is, there-
fore, a possible mechanism via which growth control is
exerted. One example of such a growth factor is TGF-/3,3
which generally acts as a growth inhibitor of various epi-
thelial cell lines (5, 6), including most epithelial breast
tumor cell lines (7). Three different human TGF-/3 subtypes
(TGF-/31 , -f32, and -/33) have been cloned, which share high
degrees of protein homology. Estrogens have been shown to
decrease the synthesis of TGF-￿3 in several hormone-depen-
dent breast tumor cell lines, whereas growth-inhibiting anti-
estrogens had the reverse effect (8). TGF-f32 and -￿3 are
down-regulated by the estrogen E2 at the protein and mRNA
levels, whereas TGF-/3i expression is not affected (9, 10).
TGF-/3s are generally expressed in breast tissue (1 1) and
seem to be important negative regulators of normal mam-
mary epithelial cell proliferation both in vitro (1 2, 13) and
in vivo, as demonstrated in mice (i 4). In breast tumors, all
TGF-￿ isoforms are also secreted (1 1), and enhanced ex-
pression of TGF-f31 in particular at both the mRNA and
protein levels appears to be associated with disease pro-
gression (1 5-20) and metastasis (20). In agreement with
this, all human breast tumor cell lines secrete TGF-3s (7, 13,
21-23), and levels are elevated with increased malignancy
(21-23). It has been shown that elevation of TGF-f3 expres-
sion can enhance mammary tumor cell malignancy, prob-
ably via paracrine interactions (24). Given the fact that
proliferation of normal epithelial cells is virtually abolished
by small amounts of TGF-f3 (1 2, 13), it seems likely that the
epithebial tumor cells have developed some sort of insen-
sitivity to the increased amounts of TGF-￿3 that surround
them.
Activins, which also belong to the TGF-/3 superfamily, are
currently regarded as important regulators of cell differen-
tiation and proliferation (25, 26). Different isoforms of ac-
tivin exist that result from the dimerization of two related
subunits (/3A and ￿B) in various combinations. Expression
of the /3Af3A homodimer, known as activin A, is found
in many tissues (26). At present, expression of activins in
normal and malignant breast tissue has not been studied,
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Fig. 1. Effects of TGF-j31 and activin A on the prolif-
eration of human breast tumor cells. ER-positive (ER+)
cell lines MCF7, T47D, T47D(ATCC), and ZR75-1
were grown for 48 h in the presence of 10￿ M E2 and
in the presence of 2 np/mI TGF-f31 (1) or 50 ng/mI
activin A (0). [3HlThymidine was incorporated for the
last 16 h. Proliferation is depicted relative to the
l3Hlthymidine incorporation in the presence of E7
alone. ER-negative (ER-) cell lines BT2O, Hs578T,
MDA-MB231 , and MDA-MB468 were tested similarly
with the omission of E2. A representative experiment is
shown with determinations in triplicate; bars, SEM.
nor are data available on the effects of activin on breast
tumor cell proliferation.
Both TGF-f3s and activins exert their action via binding to
specific cell surface receptors, which belong to the family of
serine/threonine kinases. Two different classes of these re-
ceptors, types I and type, have been identified (26, 27),
which must form a heteromeric complex to be functional.
The type I receptors require a type II receptor to bind ligand,
and type II receptors require a type I receptor for signaling
but not for binding (28-31 ). An additional third high affinity
receptor for TGF-f3 has been identified, the type III receptor
or betaglycan, which backs a serine/threonine kinase do-
main, but appears to play a robe in presenting TGF-/3 to the
type II receptor (32). TGF-f32 in particular requires the
presence ofthe type III receptor to exert its biological action
(32, 33). To date, five different human type I receptors have
been cloned (30, 34), denominated ALK-1 to -5, two human
activin type II receptors (IIA and IIB; Refs. 35 and 36), and
one human type II receptor for TGF-/3 (TGF-f3 receptor II;
Ref. 37). When overexpressed in cells, complexes between
TGF-/3 receptor II or activin receptor II and all different ALKs
can be detected upon bigand binding (27, 38), but activin
preferentially binds to and signals through activin type II
receptors when expressed in combination with the type I
receptors ALK-2 or -4, whereas TGF-/3 favors the TGF-/3
receptor II in combination with ALK-5 (38). Also in cells that
express endogenous receptors, only complexes between
ALK-5 and TGF-/3 receptor II were detected (38).
Various TGF-f3-resistant human tumor cell lines have
been shown to express bow or undetectable bevels of TGF-f3
receptors (39-44). In Hep3B hepatoma cells, introduction
of the TGF-f3 receptor lb was sufficient to restore TGF-j3
sensitivity (44), indicating that all other signal transduction
components, including TGF-/3 type I receptors, are present
and functionally intact in these cells. Some human breast
tumor cell lines have also been found to be TGF-/3 resistant
(7), and a correlation between ER expression and TGF-/3
resistance has been suggested (45), although other authors
also found ER-positive cell lines that are sensitive to TGF-f3
(8, 9, 46, 47).
In the present study, we examined a panel of both ER-
positive and -negative cell lines for resistance to TGF-/3 and
any defects in expression of the different TGF-f3 receptors.
Since activins exert their action via transmembrane recep-
tors that are closely related to the TGF-f3 receptors, we also
tested these cell lines for their sensitivity to activin A, as well
as the expression of activin receptors. We found some of the
ER-positive (two T47D variants, ZR75-1) as well as some of
the ER-negative cell lines (MDA-MB231 and MDA-MB468)
to be resistant to TGF-/3. The TGF-j3-resistant ER-positive
cell lines either backed expression of the TGF-/3 receptor II
(both T47D variants) or expressed very low bevels of this
receptor (ZR75-1 cells). Introduction of the TGF-f3 receptor
II in one of the T47D cell lines restored sensitivity for both
TGF-/31 and -/32 with respect to inhibition of anchorage-
dependent and -independent proliferation. The degree of
inhibition of proliferation correlated with the expression
level of the newly introduced receptor. By contrast, all
ER-positive cell lines were growth inhibited by activin A,
whereas the ER-negative cell lines were resistant. In two cell
lines (BT2O and Hs578T), resistance to activin could be due
to the lack of sufficient receptors for activin. In two other
ER-negative cell lines (MDA-MB231 and MDA-MB468),
activin resistance is apparently located downstream of the
receptors, since binding of activin to type I and lb receptors
was clearly detected.
Results
Sensitivity of Breast Tumor Cell Lines to TGF-￿3 and
Activin A. The effect of TGF-/3 on the E2-induced probifer-
ation of four ER-positive cell lines was first tested. MCF7
and ZR75-1 cells and two variants of the T47D cell line,
named T47D and T47D(ATCC), which differ in their
response to progestins (47), were grown in the presence of
E2 (1 0￿ M) and in the absence or presence of TGF-31 (2
ng/ml) for 48 h. Four ER-negative cell lines (BT2O, Hs578T,
MDA-MB-231 , and MDA-MB-468) were tested in the same
manner without E2, since these cell lines back ER. As shown
in Fig. 1, proliferation of the MCF7, BT2O, and Hs578T cell
lines is clearly inhibited, with the Hs578T cell line being the
most sensitive. Two variants ofthe T47D cell line, as well as
ZR75-1, MDA-MB-231, and MDA-MB-468 cells, are resis-
tant to TGF-j3.A
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Fig. 2. Expression of TGF-￿ receptor II mRNA in hunian breast tumor cells.
A, RNase protection assay on total RNA from several human breast tumor
cell lines. Lanes I and 2, undigested probes for ￿-actin and TGF-(3 receptor
II. respectively. Lanes 3-i 1, protected fragments resulting from the hybrid-
ization of 20 pg of tRNA (Lane 3) or 20 ig of total RNA (Lanes 4-li) with
the TGF-f3 receptor II and ￿-actin probes after digestion with RNase A. B,
quantification o RNase protection assay. Data are the quantification of three
independent experiments using the amount of ￿-actin as an intern,tl stan-
d,irrl, relative to the highest level of expression detected in Mt)A-MB2 3I
cells; bars, SEM. Numbering corresponds to the lanes in A.
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The same panel of human breast tumor cell lines was also
tested for sensitivity to activin A. In this case, the ER-positive
cell lines MCF7, ZR75-1, and both T47D variants were
inhibited by activin A (50 ng/ml), with ZR75-1 cells being
the most sensitive. All four ER-negative cell lines were
resistant to the growth-inhibitory potential of activin (Fig. 1).
Therefore, no clear correlation was observed between re-
sistance to TGF-/3 and/or activin, since some cell lines are
resistant to TGF-j3 and activin A (MDA-MB231 and MDA-
MB468), whereas others are only resistant to either TGF-/3
(both T47D cell lines and ZR75-1 ) or activin A (Hs578T and
BT2O), or to neither of the two factors (MCF7).
Expression of TGF-fJ and Activin Receptors in Human
Breast Tumor Cells. To investigate whether resistance to
TGF-f3 and activin in breast tumor cell lines could be ex-
plained by the absence of the respective receptors, expres-
sion of receptors for TGF-f3 and activin was examined. First,
RNase protection assays with probes for the TGF-/3 types II
and I receptors were performed on total RNA isolated from
these cell lines. High levels of mRNA encoding the TGF-￿
receptor II were detected in all ER-negative cell lines
(Fig. 2). In ER-positive cell lines, the situation is different.
MCF7 cells express TGF-j3 receptor lb mRNA, albeit at a
much bower level than ER-negative cell lines (Fig. 28),
while no expression was detectable in either of the T47D
variants and virtually no expression in ZR75-1 cells (Fig. 2).
To verify the absence of expression in the two T47D van-
ants, cDNA was synthesized from the same RNA and used
for RT-PCR with primers directed against the region encod-
ing the senine/threonine kinase domain of the TGF-/3 recep-
ton II. Again, expression of the TGF-f3 receptor II was un-
detectable in the two T47D variants (Table 1), confirming
the expression data obtained with the RNase protection
technique (Fig. 2). Southern blot analysis showed that the
lack of expression in the two T47D cell lines is not due to
a genetic loss of the TGF-/3 receptor lb gene (data not
shown).
RNase protection analysis with a probe specific for a
TGF-￿3 type I receptor (ALK-5) showed that this receptor is
present in all cell lines, although some cell lines, particu-
barby Hs578T, expressed very bow bevels (Fig. 3). RT-PCR
was performed with primers directed against ALK-5 and the
TGF-f3 type III receptor. As in the RNase protection assays,
ALK-5 was detectable in all cell lines (Table 1 ). mRNA for
the TGF-￿ receptor III was detected in all cell lines except
in ZR75-1 cells, which also had only low levels of type II
receptor expression (Fig. 2).
Next, expression of TGF-/3 receptor protein was assessed
by the ability of these cells to bind TGF-￿1 . Upon binding
to its receptors, iodinated TGF-/31 was chemically cross-
linked to its receptors, and lysates were subjected to SDS-
PAGE. With this technique, receptor complexes have been
identified previously as the TGF-f3 I, II, and Ill receptors. As
shown in Fig. 4, types I, II, and Ill receptors were detected
in the MCF7 cell line (Fig. 4, Lane 1) and in all four
ER-negative cell lines (Fig. 4, Lanes 5-8). Binding of
TGF-￿1 to type I receptors was clearly detected in Hs578T
cells (Fig. 4, Lane 6), although only bow levels of ALK-5
mRNA expression were detected in this cell line (Fig. 3).
This may be caused by the high bevels of type II receptor
expression in these cells (Fig. 2), resulting in efficient com-
plex formation between ALK-5 and the type II receptors
upon ligand binding. However, we cannot exclude the
possibility that type I receptors other than ALK-5, which are
also expressed in this cell line (e.g., ALK-2 or ALK-4, see
1 2 3 4 5 6 7 8 9 10 11
B 120
below), contribute to the TGF-j31 -type I receptor complex
observed (Fig. 4). In the two T47D variants (Fig. 4, Lanes 2
and 3), binding to the type III receptor could be detected,
but no binding to type I and lb receptors, confirming the
absence of TGF-/3 receptor II expression in these cells. In
ZR75-1 cells, binding of TGF-/31 was virtually absentTable 1 Expression of TGF-f3 and activin receptors in human breast
cancer cells
mRNA expression of TGF-j3 types I, II, and III receptors and activin types
I and II receptors in human breast tumor cell lines were detected by RT-PCR,
using primer pairs described in “Materials and Methods.”
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Fig. 3. Expression of ALK-5 mRNA in human breast tumor cells. A, RNase
protection assay on total RNA froni several human breast tumor cell lines.
Lanes 1 and 2, undigested probes for f3-actin and ALK-5, respectively. Lanes
3-1 1, protected fragments resulting from the hybridization of 20 pg of tRNA
(Lane 31 or 20 pg of total RNA (Lanes 4-111 with the ALK-5 and f3-actin
probes after digestion with RNase A. B, quantification of RNase protection
assay. Data represent the quantification of three independent experiments
using the amount of f3-actin as an internal standard, relative to the highest
level of expression detected in ZR75-1 cells; bars, SEM. Numbering corre-
sponds to the lanes in A.
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Receptor Type
TGF-f3
I
receptors
II III
Ac tivin receptors
I II
ALK-5 ALK-2 ALK-4 IIA lIB
ER-positive
MCF7 +“ + + + + + +
T47D + - + + #{247} + +
T47D(ATCC) + - + + + + +
ZR75-1 + + - + + + +
ER-negative
BT2O + #{247} + + #{247} + +
Hs578T + + + + + + +
MDA-MB231 #{247} -f- + + + + +
MDA-MB468 + + + + + + +
PCR products were
ethidium bromide.
loaded on 1#{176}/ agarose gels and visualized with
(Fig. 4, Lane 4), which is in accordance with the bow
expression levels of TGF-/3 receptor II mRNA in these cells
(Fig. 2) and the absence of type Ill receptor mRNA expres-
sion (Table 1 ). In summary, we conclude that in the case of
T47D, T47D(ATCC), and ZR75-1 cells, resistance to TGF-/3
could be caused by the lack of sufficient type II receptors,
but that in other cell lines (MDA-MB-231 and MDA-MB-
468), the cause for resistance is probably located down-
stream of the receptors.
To test whether resistance to activin could be explained
by the absence of one of the components of the receptor
complex, RT-PCR was performed on mRNA from all cell
lines with primers directed against the activin receptors IIA
and IIB, as well as ALK-2 and ALK-4, two type I receptors.
Using this method, no receptor-rebated mechanism for the
resistance to activin as observed in the ER-negative cell
lines was found, since mRNA encoding the activin recep-
tons hA and lIB, as well as ALK-2 and ALK-4, was detected
in all cell lines (Table 1).
Since the presence of mRNA encoding the different ac-
tivin receptors does not necessarily indicate that functional
cell surface receptors are present, we examined the binding
ability of activin to its cell surface receptors by chemical
cross-linking with iodinated activin. Activin binding was
detected in the ER-positive cell lines (Fig. 5, Lanes 1-4) and
also in the ER-negative cell lines MDA-MB231 and MDA-
MB468 (Fig. 5, Lanes 7and 8). In BT2O and Hs5781 cells,
only very little activin binding was detected (Fig. 5, Lanes 5
and 6). Therefore, we conclude that the resistance to activin
found in these cell lines (Fig. 1) could be caused by the lack
of sufficient cell surface receptors. In MDA-MB231 and
MDA-MB468 cells, the cause of resistance to the antipro-
liferative effects of activin is probably located downstream
of the receptors, since these cell lines are clearly capable of
activin binding.
Isolation and Characterization of T47D Cells Stably
Transfected with the TGF-￿ Receptor II. To examine
whether the lack of expression of the TGF-j3 receptor II
could account for the resistance to TGF-/3s in some of the
breast tumor cell lines, we stably tnansfected the T47D cell
line with an expression vector encoding the TGF-￿ receptor
II under control of a cytomegabovinus promoter (44). As a
control, cells were also transfected with the empty expres-
sion vector. After selection in G418-containing medium,
clones were isolated and analyzed by RNase protection.
Several positive clones were identified with different- 70
Cell Growth & Differentiation 1155
type Ill [
typell [
typel [
a,
￿c
￿*￿￿$￿Mw (kD)
- 100
- 43
- 30
typell [
a, ￿ ￿
￿c
￿$4￿t￿MW (kD)
f￿ ￿ww￿ ￿ ‘s￿￿
- 100
typel [ ￿ #{149}￿ :￿-.￿ -70
￿.
- 43
- 30
12345678
Fig. 4. Binding of TGF-)31 to cell surface receptors in human breast tumor
cells. Upon binding, 25l-labeled TGF-f31 was chemically cross-linked to its
cell surface receptors. Complexes were separated on an 8/, SDS-PAGE gel.
Left, specific complexes; right, molecular weight markers in kilodaltons.
expression bevels (Fig. 6A). Highest bevels of expression,
comparable to those detected in MDA-MB-231 cells,
were found in clone 2B3 (Fig. 2). The mRNA bevel in
clone 1 E6 was 4-5 times lower and equaled the bevels
detected in MCF7 cells (Fig. 2). In addition, several
clones were isolated that had been transfected with the
empty expression vector, which were all negative with
respect to TGF-j3 receptor II mRNA expression. One of
those is depicted (neo). Expression of ALK-5 was also
investigated with RNase protection and was approxi-
mateby equal in all clones (Fig. 68).
Expression of TGF-f3 receptor protein in the transfectants,
the T47D parent cell line and a neo clone was assessed by
their ability to bind TGF-f31 , as described above. Only weak
binding of TGF-f31 to the TGF-/3 receptor Ill could be de-
tected in T47D and neo cells, whereas neither the type I nor
the type II receptors were detectable. In the clones 2B3 and
1 E6, type Ill receptors were also evident, in addition to type
I and II receptors (Fig. 7A). Highest bevels of TGF-/3 type II
receptor protein was found in clone 2B3, in agreement with
mRNA bevels (Fig. 6A). The cross-linked type I receptor is
likely to be ALK-5 detected in the RNase protection (Fig.
68). This protein is probably also present in the parent cell
line but cannot be detected in the chemical cross-link be-
cause of its inability to bind TGF-/3 in the absence of the
type lb receptor (28-31).
Functionality of the TGF-f3 receptors detected in the
RNase protection assay was examined in proliferation as-
says. For this purpose, cells were grown in the presence of
E2 and in the additional presence of various concentrations
of TGF-f31 or -/32. Whereas both the parent cell line and the
neo clone proved to be insensitive to the growth-inhibitory
12345678
Fig. 5. Binding of activin A to cell surface receptors in human breast tumor
cells. Upon binding, 25I-Iabeled activin A was chemically cross-linked to its
cell surface receptors. Complexes were separated on an 8”/ SDS-PAGE gel.
Left, specific complexes; right, molecular weight markers in kilodaltons.
activity of TGF-f31 and -p2, the E2-induced proliferation of
clone 1 E6 and 2B3 was inhibited in a dose-dependent
fashion (Fig. 7, B and C). Maximum bevels of inhibition
were reached at 0.5 ng/mb in both clones. Furthermore, at
saturating concentrations of TGF-f3 (1-2 ng/ml), clone 2B3
was inhibited to 25% of the stimulated values, whereas the
proliferation of clone 1 E6 was inhibited only to 80%,
clearly indicating that the magnitude of the response de-
pends on the level of TGF-j3 receptor lb expression. Similar
results were obtained in [3Hlthymidine incorporation as-
says under the conditions described above (data not
shown). To characterize the transfectants in more detail,
other factors that have been shown previously to inhibit the
E,-induced proliferation of T47D cells were tested. The
anti-estrogen 4’-hydroxytamoxifen, retinoic acid, and
the synthetic progestin Org2058 inhibited proliferation of
the transfectants to the same extent as the parent cell line,
indicating that other growth-inhibitory responses are pre-
served in the transfectants (data not shown).
Sensitivity to TGF-/31 was also tested in anchorage-inde-
pendent growth. Colony formation of clone 2B3 and 1E6 in
soft agar in the presence of E2 was inhibited by TGF-/31,
while no effect was detected in either T47D or neo cells
(Fig. 7D). As was true for the anchorage-dependent growth,
the inhibition of colony formation by TGF-/31 was stronger
in clone 2B3 than in clone 1 E6.
In summary, sensitivity to TGF-/31 and -/32 can be re-
stored in T47D cells by introduction of the TGF-/3 receptor
II. Since TGF-j31 signaling requires type I and II receptors
(28-31 ), and TGF-￿2 requires types I, II, and Ill receptors to
exert its action (32, 33), the TGF-/3 receptor II transfectants
tested here express functional type I and Ill receptors, as0
c’s
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Fig. 6. Expression of TGF-f3 receptor mRNA in T47D cells stably transfected with the TGF-f3 receptor II. A, RNase protection assay on T47D transfectants. Lanes
1 and 2, undigested probes for j3-actin and TGF-f3 receptor II, respectively. Lanes 3-7, protected fragments resulting from the hybridization of 20 pg oftRNA (Lane
3) or 20 pg oftotal RNA (Lanes 4-7) with the TGF-j3 receptor II and j3-actin probes after digestion with RNase A. B, as in A, but now with a probe against ALK-5
instead of the TGF-g3 receptor II.
well as all other, at present largely unknown, signal trans-
duction components.
Discussion
In the present study, we show that resistance of breast tumor
cell lines to growth inhibition by TGF-/3 is frequently linked
to defective receptor expression. TGF-f3 resistance has been
reported to correlate with ER positivity (45), but like others
(8, 9, 46), we found this correlation not strict (Ref. 47 and
this study). Reduced expression of the TGF-/3 receptor II, as
found in ZR75-i cells, or the total absence of TGF-/3 re-
ceptor II expression, as in the two 147D cell lines, provides
a plausible explanation for the resistance to TGF-/3. Very
recently, two other hormone-dependent breast tumor cell
lines were shown to be TGF-j3 resistant and to express bow
or undetectable expression of the TGF-f3 receptor II. In
ER-positive CAMA-1 cells, expression ofthe TGF-f3 receptor
II was absent (49), whereas in a particular MCF7 variant,
only very bow levels of this receptor were found (50). Only
in MCF7 (50) and T47D cells (this study) has TGF-/3 resis-
tance formally been proved to be caused by the back of
sufficient TGF-13 type lb receptors. In both cell lines, sensi-1￿
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Fig. 7. Binding of TGF-f3 and effects on the proliferation of T47D cells stably transfected with the TGF-f3 receptor II. A, binding of TGF-)31 to its receptors in
T47D cells stably transfected with the TGF-f3 receptor II. Upon binding, 25IIabeIed TGF-f3i was chemically cross-linked to its cell surface receptors. Complexes
were separated on an 8% SDS-PAGE gel. Left, specific complexes; right, molecular weight markers in kilodaltons. B, effect ofTGF-f31 on the proliferation of T47D
transfectants. The parent T47D cells (Al. clone 2B3 (#{149}(, clone 1 E6 (#{149}), and a neo clone (￿( were treated with various concentrations of TGF-j31 in the presence
of 10￿ M E2. After 4 days, the total amount of DNA/well was determined as a measure for proliferation, relative to the stimulation by E, alone. A representative
experiment is shown with determinations in triplicate; bars, SEM. C, as in B, but now in the presence of various concentrations of TGF-￿2. 0, colony formation
in soft agar of the T47D transfectants. Cells were grown as described in ‘Materials and Methods,” in the presence of 2 ng/ml TGF-fJl . Colonies were scored after
10-1 4 days. Colony formation is depicted relative to amount of colonies formed in the absence of TGF-f31 ; bars. SEM.1158 TGF-p and Activin Resistance in Breast Tumor Cells
tivity to TGF-j3 was restored upon introduction ofthe TGF-/3
receptor II, indicating that all other signal transduction com-
ponents, including TGF-f3 type I receptors, are present and
functionally intact in these cell lines. Interestingly, in the
MCF7 transfectants, the effect of TGF-(3 on anchorage-
independent proliferation and tumonigenicity appeared
to correlate with the level of TGF-j3 receptor II expres-
sion, whereas anchorage-dependent proliferation was in-
hibited independent of the receptor levels (50). These
findings suggest that under specific assay conditions,
effectors downstream ofthe receptors were limiting in the
MCF7 transfectants. In contrast, we found the effects of
TGF-/3 on both anchorage-dependent and -independent
proliferation of the T47D transfectants to be clearly de-
pendent on the TGF-/3 receptor II levels. In addition, the
T47D transfectants respond similarly to TGF-￿31 and -/32,
indicating that functional type Ill receptors are also
present.
In human cells other than breast cancer cell lines, such as
T-cell lymphomas (39), retinoblastoma (40), gastric cancer
(4i ), and squamous carcinoma (42, 43), resistance to TGF-j3
has also been found to be caused by reduced levels of the
TGF-j3 receptor II. Furthermore, chemical mutagenesis of
MvLui mink lung epithelial cells (Si), or exposure of
Hep3B hepatoma cells to low concentrations of TGF-/3i
(44), has also led to the isolation of TGF-f3-resistant variants
lacking TGF-j3 receptor II expression. Specific loss of ex-
pression of the TGF-f3 receptor II, therefore, seems to be a
common mechanism favored by cells to yield TGF-/3 resis-
tance. The fact that TGF-/3 binding is often not detected in
cells lacking the type II receptor is probably due to the fact
that type I receptors are incapable of binding TGF-j3 in the
absence of type II receptors and not to the fact that expres-
sion of the type I receptor is lost as well. The observation
that in Hep3B cells (44), MvLui cells (29), MCF7 cells (50),
and T47D cells (this study) sensitivity could be restored by
introduction of the TGF-/3 receptor II only, supports this
view.
Autocri ne/paracri ne mechan isms involvi ng TG F-/3 have
been suggested previously to be important in the growth
regulation of human breast tumor cell lines by steroids.
Stimulation of proliferation by E2 has been described as
correlating with a decrease in the levels of secreted TGF-/3,
whereas the antiproliferative anti-estrogen tamoxifen
causes an increase in the secretion of TGF-/3 by MCF7 cells
(8), and growth inhibition of T47D cells by the synthetic
progestin gestodene was also shown to correlate with in-
creased TGF-/3 secretion (46). However, ii et a/. (48) have
recently shown that the TGF-/3-resistant cell line CAMA-1 is
growth-inhibited by anti-estrogens. In addition, TGF-f3-re-
sistant T47D cells are inhibited by the anti-estrogen tamox-
ifen (data not shown) and progestins, including gestodene
(47). Since no expression of the TGF-/3 receptor II was
detected in CAMA-i cells (48), as we have shown here for
the T47D cell line, we conclude that at least in these cell
lines, progestins and anti-estrogens inhibit proliferation via
a pathway independent of TGF-/3.
Since resistance to TGF-/3 is often due to absence or
reduced expression of the TGF-/3 receptor II in ER-positive
cells (Refs. 45, 48, and 49 and this study), as opposed to
ER-negative cell lines, it is possible that E2 represses the
expression of this receptor. As was also shown for CAMA-i
cells (48), we were unable to detect expression ofthe TGF-J3
receptor II in T47D cells after steroid deprivation or after
treatment with progestins, which often oppose the effects of
estrogens (data not shown). If and how steroids repress
TGF-f3 receptor II expression in these cell lines is yet un-
clear.
If cells apparently express sufficient TGF-/3 and activin
receptors, as in the case of the MDA-MB231 and
MDA-MB468 cell lines, resistance to both ligands must be
located elsewhere. Recently, several mechanisms of TGF-f3
resistance have been found, based on the earlier findings
that TGF-j3 arrests cells in the late G1 phase ofthe cell cycle
(SO). The phosphorylation state of the retinobbastoma gene
product (Rb) is indicative of the location of a cell in the
cycle, since it is hypophosphorylated specifically in the G1
phase. Hypophosphorylation of Rb has been observed after
treatment of cells with TGF-/3 (51), preventing them enter-
ing S-phase. Specific interactions between the G1 cyclmns
(cyclmns C, Di , D2, D3, and F), the cdks, and the recently
discovered cyclin-cdk inhibitor proteins (cdis; Ref. 52) are
thought to regulate the phosphorylation of Rb. TGF-j3 reg-
ulates the expression and/or enzymatic activity of several of
these proteins. Overexpression of cyclmn Di , a common
event in breast tumors (53, 54), was shown to result in
TGF-/3 resistance in esophageal epithebial cells (55). Over-
expression of cdk4, the target for cyclmn Dl , can also render
cells TGFf3 resistant (56). In addition, overexpression of
cyclin E, a cyclmn whose expression is also repressed by
TGF-/3 (57), also often occurs in human breast tumors (53,
54), but this has not been shown to lead to TGF-/3 resis-
tance. Furthermore, the activity of the cdi p27K￿￿l (58) and
the expression of the cdi p1 5 (59) are regulated by TGF-/3,
and deregulated expression ofthese proteins is, therefore, a
potential site for TGF-f3 resistance. In addition, the trans-
forming proteins of adenovirus (El A) and SV4O (T antigen),
which are able to bind to Rb, are also able to confer TGF-j3
resistance (51 , 60). Whether any of these mechanisms ac-
counts for the resistance to TGF-f3 observed in MDA-
MB231 and MDA-MB468 cells remains to be established.
Interestingly, we found both cell lines to be resistant to
activin. Since, like TGF-f3 (51), activin causes hypophos-
phorylation of Rb and the subsequent arrest of cells in the
late G1 phase of the cell cycle (61), it is tempting to spec-
ulate that the mechanisms causing this hypophosphoryla-
tion, which involve the cyclmn-cdk interactions described
above, are shared by activin and TGF-f3. In that case, cross-
resistance to activin and TGF-/3 could be caused by a single
event. Alternatively, defects in receptor function or signal
transduction could account for resistance to TGF-/3 and/or
activin, but experimental evidence in that direction is pres-
ently lacking.
Interestingly, we found no strict correlation between ER
content and TGF-/3 sensitivity but did find that the ER-
positive cell lines were growth inhibited by activin and that
all ER-negative cell lines tested in this study appeared to be
resistant. Whether loss of sensitivity to activin is an impor-
tant step in the progression of breast tumor cells to an
autonomously growing phenotype will be the subject for
future research.
Materials and Methods
Materials. A phenol red-free 1 :1 mixture of DMEM and
Ham’s Fl 2 medium (DF) was obtained from GIBCO (Grand
Island, NY). FCS was purchased from Integro (Linz, Austria);
bovine insulin, E2, human transfernin, all-trans-retinoic
acid, and BSA were from Sigma Chemical Co. (St. Louis,
MO). Trypsin and EDTA used for cell culture were obtainedCell Growth & Differentiation 1159
from Flow Laboratories (Irvine, Scotland). The progestin
Org2058 was provided by Organon International (Oss, the
Netherlands), and 4’-hydroxytamoxifen was obtained from
ICI (Macclesfield, England). DCC-FCS was prepared by
treatment of FCS with DCC to remove steroids, as described
(62). TGF-j31 was purified from human platelets as de-
scnibed (63); human recombinant TGF-f32 and bovine re-
combinant activin A were kind gifts of Drs. N. Herrmann-
Erlee (Leiden, the Netherlands) and Dr. P. de Waele
(lnnogenetics, Ghent, Belgium), respectively.
Cell Culture and Proliferation Assays. MCF7 cells were
kindly provided by Dr. C. Quinmn-Stnicker (Strasbourg,
France) and T47D cells by Dr. R.L. Sutherland (Sydney,
Australia). All other cell lines were obtained from the ATCC.
Cells were cultured in bicarbonate-buffered DF medium
containing phenol red supplemented with 7.5% FCS in a
7.5% CO2 humidified atmosphere. Cells were passaged
twice a week using trypsin and EDTA.
The effect of mitogens on DNA synthesis was tested as
described previously (62). In short, cells were plated at a
density of 1 .0 X 104/cm2 in 24-well plates in DF Containing
30 nM sebenite, 10 pg/mI transfernin, and 0.2% BSA (referred
to as DF+), supplemented with 5% DCC-FCS. After 24 h,
the medium was refreshed, and the compounds to be tested
were added in 2-[bis(2-hydroxy-ethyl)amino] ethanesul-
fonic acid (50 mM; pH 6.8) buffered DF+. After 4 days, or
8 days in the case ofT47D(ATCC) cells, the total amount of
DNA per well was determined by fluorescent staining with
Hoechst 33248. To monitor DNA synthesis, the cells were
treated with [3H]thymidmne (1 .0 pCi/mb) for the last 16 h of
a 48-h hormone incubation. Subsequently, the cells were
washed with tnichloroacetic acid and bysed with NaOH,
followed by liquid scintillation counting as described (64).
ANOVA was used to test for differences in the means of data
points. Differences were considered significant when !￿
were 0.05 or less.
To test anchorage-independent growth, 1.0 x 10￿ cells/
cm2 were plated in a 50-mm Petni dish in DF+ (supple-
mented with 5% DCC-FCS) in 0.375% agar onto a basal
layer of 0.5% agar, as described by Todaro et a!. (65).
Colony formation was tested in the presence of E2 (1 0￿ M)
and in the absence or presence of 2 ng/ml TGF-f31 . After 10
days, colonies were scored counting 20 random fields,
corresponding to 2.3% of the total dish area. Aggregates
larger than 10 cells were counted as 1, smaller aggregates as
0.5. Experiments were performed in quadruplicate.
RNA Isolation and RNase Protection Assay. Total RNA
was isolated by the acid-phenol method of Chomczynski
and Sacchi (66). For RNase protection analysis, riboprobes
were generated by in vitro transcription of the plasmids
described below, using 17 RNA polymerase for the TGF-j3
receptor II and ALK-5 probes and SP6 polymerase for the
/3-actin probe. A 236-bp BgIlI-Smal fragment from the hu-
man TGF-/3 receptor II was cloned into pBbuescript 5K-,
which upon linearization with XbaI results in a 305-bp
template, and a 80-bp EcoRI-Hindlll fragment from the
human /3-actin was cloned into pGEM-3Z, providing a
130-bp probe upon linearization with EcoRl. For the human
ALK-5 probe, a 228-bp BamHI-XhoI fragment from the PCR
fragment described below was cloned into pBluescnipt 5K-,
which results in a 267-bp probe after linearization with
Xbal. The /3-actin probe was labeled to a 10 times bower
specific activity. Total RNA (20 pg) was hybridized for 16 h
at 45#{176}C with 10￿ cpm TGF-/3 receptor II probe and 10￿’ cpm
of /3-actin probe in a final volume of 25 p1 Containing 80%
formamide, 40 mM 1,4-piperazinediethanesulfonic acid,
0.4 M NaCI, and 1 mM EDTA. Subsequently, samples were
digested with RNase A (20 pg/mI) for 30 mm at room
temperature. Digestion was terminated with 0.1 25 mg/mI
proteinase K and 0.5% SDS. After phenol:chloroform (1 :1)
extraction, samples were precipitated with ethanol in the
presence oftRNA (5 pg/sample), washed with 70% ethanol,
dried, and separated on a 6% polyacrylamide sequencing
gel. Protected fragments were quantified on a Phospholm-
ager (Molecular Dynamics) using ImageQuant software.
Chemical Cross-Linking of [‘25IITGF-f3. Activin A and
TGF-f3 were iodinated using a modified chloramine-T
method (67). For TGF-/3 and activin binding, cells were
seeded in DF containing 7.5% FCS in culture dishes (4,, 10
cm) at a density of 2 X 1 06 cells/dish. After replacement of
the media with binding medium [HEPES buffered DF (pH
7.5) containing 0.2% BSA], cells were incubated with
[125l]TGF-/3 or activin for 2 h at 4#{176}C, with gentle shaking.
Then, the excess of radiolabeled ligand was removed by
gently washing with HEPES-buffered saline containing 0.9
mM CaCl2 on ice. TGF-f3 and activin were cross-linked by a
30-mm incubation with 1 m￿ bis-sulfosuccmnimidyl suber-
ate (Pierce, Rockford, IL) in HEPES-buffered saline at 4#{176}C.
Subsequently, the cross-linking was quenched by the addi-
tion of 1OX quench [1 0 mr￿i Iris (pH 7.5), 2 mM EDTA, and
200 m￿t glycin], and the cells were bysed in lysis buffer [1 %
Triton X-100, 20 mM Iris (pH 8.0), 137 mtvt NaCI, 10%
glycerol, 1 mM phenylmethylsulfonyl fluoride, 0.5 pg/mI
aprotinin, and 0.5 pg/mI leupeptin]. TGF-/3 or activin re-
ceptors were precipitated with wheat germ agarose. Finally,
samples were run on a 8% SDS-PAGE gel, and TGF-j3 or
activin binding proteins were identified by autoradiography.
RT-PCR. RT-PCR was performed exactly as described
(68). For the TGF-/3 type II receptor, 5’-TACAGGAGTAC-
CTGACGTCGGCA-3’ as forward primer and 5’-GGCTC-
CAGAAGTCCTAGAATCC-3’ as reverse primer were used,
amplifying a region corresponding to 998-1 295 bp of the
human sequence (37), at an annealing temperature of 52#{176}C.
For the human TGF-/3 type III receptor, 5’-AATGGCTCCT-
GTGGCAATAG-3’ as forward primer and S’-TTGCAC-
CTCTTCTGGCTCTC-3’ as reverse primer were used, am-
plifying a region corresponding to 1647-1 950 bp of the
human sequence (69), at an annealing temperature of 49#{176}C.
For the activin type IIA receptor, S’-GCAAGGTTGTTG-
GCTGGAIGAT-3’ was used as forward primer and 5’-
GGTGGCTTCGGTGTAACAGGAT-3’ as reverse primer,
corresponding to 295-474 bp of the human sequence (35)
at an annealing temperature of 52#{176}C. For the activin type IIB
receptor, 5 ‘-CGCTGCTGCCCATTGGAGGC-3 ‘ was used
as forward primer and 5’-CACCGGGAGTGGTGCT-
GTGG-3’ as reverse primer, a kind gift of Dr. R. H. N. van
Schaik (Rotterdam, the Netherlands), corresponding to
429-924 bp of the human sequence (36), at an annealing
temperature of 52#{176}C. Nucleotides depicted in bold repre-
sent mismatches to the human sequence. For ALK-2, 5’-
AGATGAGAAGCCCAAGGTCAAC-3’ was used as forward
primer and 5’-AGTGCCATACTCCACGTCTCGG-3 ‘ as re-
verse primer, corresponding to 41 3-601 bp of the human
sequence (34), at an annealing temperature of 52#{176}C. For
ALK-4, 5 ‘-CGCAACACCCACTGCTGCTAC-3 ‘ was used as
forward primer and S’-ATGAGGGATCTTCCATGTCC-3 ‘ as
reverse primer, corresponding to 271 -505 bp of the human
sequence (34), at an annealing temperature of 62#{176}C. Num-
bering is based on the full-length cDNA. For ALK-5, 5’-
CGITACAGTGTTTCTGCCACCACCT-3’ was used as for-1160 TGF-f3 and Activin Resistance in Breast Tumor Cells
ward primer and 5’-AGACGAAGCACACTGGTCCAGC-3’
as reverse primer, corresponding to 98-41 2 bp of the
human sequence (30), at an annealing temperature of 52#{176}C.
As a control for cDNA synthesis, RT-PCR was also per-
formed with a primer pair specific for /3-actin (68). PCR
products were loaded on i% agarose gels and visualized
with ethidium bromide.
Isolation of Stable Transfectants. T47D cells, a kind gift
of Dr. R. L. Sutherland (Sydney, Australia) were plated at a
density of 2.0 X i04/cm2 and transfected with calcium-
phosphate coprecipitation method with 10 pg/well of either
the empty pcDNA-neol vector (InVitrogen, San Diego, CA)
or the same vector containing the human TGF-/3 type II
receptor cDNA (37). After 6 h, the medium was refreshed.
Twenty-four h later, cells were replated into SO-mm Petri
dishes, and geneticin (G41 8; 600 pg/mI) was added. Resis-
tant colonies were isolated 10-is days later and cultured
under continuous G418 selection.
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